Why Sionna Therapeutics Stock Is Crashing 91% to a Record Low
Sionna Therapeutics shares have plummeted over 90% following the failure of a key clinical trial for its cystic fibrosis drug, SION-719.
5 trends tracked about this subject — the full history, oldest to newest below.
Sionna Therapeutics shares have plummeted over 90% following the failure of a key clinical trial for its cystic fibrosis drug, SION-719.
Vertex Pharmaceuticals shares rise as rival Sionna Therapeutics sees its stock collapse following a failed cystic fibrosis drug trial.
New research reveals how transient environmental bacteria transfer genes to chronic lung infections, boosting antibiotic resistance over 10,000-fold.
Northwestern Medicine has performed a first-of-its-kind quadruple-organ transplant for a woman with cystic fibrosis who had previously received lung transplants.
Beximco Pharma has initiated the supply of a low-cost cystic fibrosis medication to patients across six countries following a patent law loophole.